---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-112750"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2023-10-31T23:59:59+00:00"
generated_at: "2026-06-09T04:48:27.076390+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kiniksa Q3 ARCALYST revenue $64.8M (+94% YoY); tracking to high end of FY guidance

## Summary
- ARCALYST net product revenue $64.8M, ~94% YoY growth; total revenue $67.0M (incl. $2.2M license).
- Net loss $13.9M vs net income $224.1M in Q3 2022 (prior year included $65.7M license revenue).
- Cash $201.1M, no debt; expected to fund operations into at least 2027.
- KPL-404 Phase 2 RA data from Cohorts 1-3 expected Q1 2024; Cohort 4 data expected Q2 2024.
- FY2023 ARCALYST revenue guidance $220-230M, tracking to high end.

## SEC filing metadata
- accession: 0001104659-23-112750
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2023-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465923112750/0001104659-23-112750-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465923112750/tm2329311-1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-112750
- JSON: https://secwatch.observer/filing/0001104659-23-112750.json
- Plain text: https://secwatch.observer/filing/0001104659-23-112750.txt

## Key facts
- Earnings Releases
  Kiniksa Pharmaceuticals International, plc reported financial results for third quarter 2023.
  - Period: third quarter 2023
  - Result: reported results
  source text: On October 31, 2023, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730430/000110465923112750/0001104659-23-112750-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.